Multiple myeloma trials in Brazil

In Brazil 24 Also abroad 704

24 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Where
Bento Gonçalves, Curitiba, Lages, Porto Alegre, Rio de Janeiro, Salvador, São Paulo
Age
18 years and over
People
410 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT05730036 · EU 2022-501396-62-00
Phase 3Taking people
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Where
Belo Horizonte, Curitiba, Joinville, Lages, Niterói, Porto Alegre, Ribeirão Preto, São Paulo
Age
18 years and over
People
915 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07222761 · EU 2024-519504-27-00
Phase 3Taking people
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Where
Barretos, Belo Horizonte, Curitiba, Fortaleza, Natal, Niterói, Porto Alegre, Ribeirão Preto, Salvador, São Paulo
Age
18 years and over
People
1,590 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00
Phase 3Taking people
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Where
Campinas, Caxias do Sul, Curitiba, Florianópolis, Rio de Janeiro, Salvador, São José do Rio Preto, São Paulo
Age
18 years and over
People
400 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07258511 · EU 2025-522007-18-00
Phase 3Taking people
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Where
Jaú, Joinville, Porto Alegre, Rio de Janeiro, Salvador, São Paulo
Age
18 years and over
People
810 worldwide
Run by
Celgene
See details and how to joinNCT05519085
Phase 1/2Taking people
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Where
Salvador, São Paulo
Age
18 years and over
People
226 worldwide
Run by
AstraZeneca
See details and how to joinNCT06106945 · EU 2023-508590-89-00
Phase 3Taking people
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Where
Nova Lima, São Paulo
Age
18 years and over
People
440 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00
Phase 3Taking people
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Where
Porto Alegre, Ribeirão Preto
Age
18 years and over
People
1,060 worldwide
Run by
Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00
Phase 1/2Taking people
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Where
Brasília, Porto Alegre, Salvador, São Paulo
Age
18 years and over
People
246 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04973605 · EU 2023-507751-30-00
Phase 3Taking people
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Where
Salvador, São Paulo
Age
18 years to 130 years
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07735637
Phase 2Enrolling by invitation
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Where
Porto Alegre, Rio de Janeiro, São Paulo
Age
18 years and over
People
70 worldwide
Run by
Sanofi
See details and how to joinNCT05669989
Phase 3Taking people
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Where
Joinville, Porto Alegre, Rio de Janeiro, Salvador, São Paulo
Age
18 years and over
People
183 worldwide
Run by
Takeda
See details and how to joinNCT06980480 · EU 2024-518420-80-00
Phase 3Taking people
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Where
São Paulo
Age
18 years and over
People
380 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07555938 · EU 2025-524028-23-00
Phase 3Taking people
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Where
Porto Alegre, Rio de Janeiro, Salvador, São Paulo
Age
18 years and over
People
1,594 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT05243797 · EU 2023-510384-36-00
Phase 3Taking people
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Where
Salvador, São Paulo
Age
18 years and over
People
508 worldwide
Run by
AstraZeneca
See details and how to joinNCT07391657
Phase 2Taking people
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Where
Brasília, Caxias do Sul, Curitiba, Salvador, São Paulo
Age
18 years and over
People
210 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06500884 · EU 2023-506260-14-00
Phase 3Taking people
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Brasília, Curitiba, Florianópolis, Joinville, Porto Alegre, Rio de Janeiro, São José do Rio Preto, São Paulo
Age
18 years and over
People
700 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07518186
Phase 3Taking people
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Where
Porto Alegre, Rio de Janeiro, Salvador, São Paulo, SP
Age
18 years and over
People
893 worldwide
Run by
Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00
Phase 3Taking people
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Where
Jaú, Niterói, Porto Alegre, Ribeirão Preto, Rio de Janeiro, Salvador, São Paulo, SP
Age
18 years and over
People
492 worldwide
Run by
Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00
Phase 1/2Taking people
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Where
Joinville, Salvador, São Paulo
Age
18 years and over
People
123 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT05714839 · EU 2022-501941-63-00
Phase 3Taking people
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Where
Salvador, São Paulo
Age
18 years and over
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07764978
Phase 3Taking people
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Where
Barretos, Joinville, Porto Alegre, Salvador, São Paulo, Teresina, Vitória
Age
18 years and over
People
520 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00
No phaseTaking people
Use of Preoperative Postbiotic Supplementation in Colorectal Cancer Surgery
Where
São Paulo
Age
18 years and over
People
164
Run by
AC Camargo Cancer Center
See details and how to joinNCT07268846
No phaseNot yet taking people in Brazil
Proteomic Analysis of Patients Undergoing Bariatric Surgery
Where
Recife
Age
18 years and over
People
103
Run by
Universidade Federal de Pernambuco
See details and how to joinNCT06787807